Drug Type Small molecule drug |
Synonyms PRT 2527, PRT2527 |
Target |
Mechanism CDK9 inhibitors(Cyclin-dependent kinase 9 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 1 | US | 12 Sep 2023 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 1 | AU | 12 Sep 2023 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 1 | CA | 12 Sep 2023 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 1 | FR | 12 Sep 2023 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 1 | DE | 12 Sep 2023 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 1 | IT | 12 Sep 2023 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 1 | PL | 12 Sep 2023 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 1 | KR | 12 Sep 2023 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 1 | CH | 12 Sep 2023 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 1 | GB | 12 Sep 2023 |
NCT05159518 (AACR2023) Manual | Phase 1 | 9 | mjzumcogaw(tgwavhszsb) = ydoftoxcvb ifwbjlhqfj (gfjctkpdnz ) View more | Positive | 14 Apr 2023 |